Bio­gen CEO Chris Viehbach­er: Im­munol­o­gy is a nat­ur­al fit at biotech, calls for 'rein­ven­tion'

From Chris Viehbach­er’s van­tage point, Bio­gen was nev­er re­al­ly a neu­ro­science com­pa­ny.

Bio­gen has launched a sig­nif­i­cant re­vamp un­der Viehbach­er, in­clud­ing the re­cent hire of Jane Gro­gan, an im­mu­nol­o­gist, as its new head of re­search. And on Thurs­day, the CEO point­ed to the com­pa­ny’s his­to­ry in mul­ti­ple scle­ro­sis as an in­di­ca­tor that the com­pa­ny has long been fo­cused on im­munol­o­gy.

“I don’t think we’re go­ing to get in­to” rheuma­toid arthri­tis, Viehbach­er said Thurs­day at the STAT Sum­mit, “but mov­ing in­to im­munol­o­gy is a nat­ur­al ad­ja­cen­cy for us, and so is rare dis­ease.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER